Cargando…
Pharmacokinetics, safety, and tolerability of inhaled remdesivir in healthy participants
Intravenous remdesivir (RDV) is US Food and Drug Administration–approved for hospitalized and nonhospitalized individuals with coronavirus disease 2019. RDV undergoes intracellular metabolic activation to form the active triphosphate, GS‐443902, and other metabolites. Alternative administration rout...
Autores principales: | Humeniuk, Rita, Juneja, Kavita, Chen, Shuguang, Ellis, Scott, Anoshchenko, Olena, Xiao, Deqing, Share, Aaron, Johnston, Matthew, Davies, Santosh, DeZure, Adam, Llewellyn, Joe, Osinusi, Anu, Winter, Helen, Girish, Sandhya, Palaparthy, Ramesh, Dresser, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651641/ https://www.ncbi.nlm.nih.gov/pubmed/37688349 http://dx.doi.org/10.1111/cts.13627 |
Ejemplares similares
-
Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting
por: Pan, David Z., et al.
Publicado: (2023) -
Reply to Yan and Muller, “Remdesivir for COVID-19: Why Not Dose Higher?”
por: Juneja, Kavita, et al.
Publicado: (2021) -
Safety, Tolerability, and Pharmacokinetics of Remdesivir, An Antiviral for Treatment of COVID‐19, in Healthy Subjects
por: Humeniuk, Rita, et al.
Publicado: (2020) -
Vaccines for Emerging Viral Diseases
por: DeZure, Adam, et al.
Publicado: (2016) -
Reply to Yan and Muller, “Single-Cell RNA Sequencing Supports Preferential Bioactivation of Remdesivir in the Liver”
por: Murakami, Eisuke, et al.
Publicado: (2021)